TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Numeric Rating Scale of Pain During Weightbearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal Endoscopic Exam Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of nerve signal loss cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC[0-t]) of Levocetirizine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Levocetirizine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak shoulder joint forces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Complications requiring further interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Positional differences of the chin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Orientation differences of the chin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: change in MAS functional index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Barthel index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in carfentanil binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kidney function trend
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Amount of resuscitation fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Platelet Transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time of hepatocellular carcinoma recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to BOS or OB, retransplantation or death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Patients with 30% Reduction in Average Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score of pain in the donor site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comprehensive curative effect
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HCV recurrence prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum level of interleukin 6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum level of interleukin IL-1β (IL-1β)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in 41Ca:Ca ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in total body insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Virological status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Detection of volatile organic compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline blood flow curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline blood perfusion units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of severe anaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Change in Daily Reflective Nasal Congestion Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in number of circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of tools filed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pharmacokinetics parameters of L-dopa absorption and elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of expected serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Low back pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients developing brisk erythema
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of patients developing moist desquamation
Endpoint domain: Adverse events/effects
Primary endpoint: 12 months overall survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Had > 95 % Epithelialization at Day 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Plasma levels of hormones and binding proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Markers of proliferation and apoptosis in breast cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Promoter-region methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUC of total gingeroids plasmatic concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort (Subjective Assessment)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hydration (Subjective Assessment)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Satisfaction for Lens
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Exercise Capacity at 6 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oxygen Consumption (VO2) at 6 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported level of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitization to Yulex
Endpoint domain: Adverse events/effects
Primary endpoint: gain of the angular vestibulo-ocular reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative saccade amplitudes per trial [°/trial] of the angular vestibulo-ocular reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amount of distension medium used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity of adverse events post-dose
Endpoint domain: Adverse events/effects
Primary endpoint: Change in RMSSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of ARQ 197
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase 2 dose (RP2D) of ARQ 197
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in the annual surgery rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Severity of airway affection measured by the Derkay papilloma severity grading scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of elevated maternal glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of meningioma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Information pursuit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oligo-progression disease rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient-reported information satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: survivorship at 10 years
Endpoint domain: Mortality/survival
Primary endpoint: lung complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of retinal morphological microvascular abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of retinal functional vascular abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of CD11b⁺cKit⁺ cells in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gene expression in circulating CD11b⁺ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with increased tumoral iodine incorporation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anatomical reattachment of the retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in total UPDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in likelihood of reported purchasing behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: predictive power of chemosensitivity measured by pCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Virological Response at Week-72
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatitis C treatment initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects completing 4 planned doses of HDMTX
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: measures of glucose control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of major congenital anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ability to visualize lung nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fugl-Meyer Motor Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients screened who are eligible
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of patients eligible who are consented
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of patients consented who complete the exercise intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of patients consented who complete pre- and post-intervention measures of the patient-reported assessment of chemotherapy-induced peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Epithelial irregularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean Seated DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median change in hot flash severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pancreas R2*
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: kidney R2*
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: success rate of block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcome of breast lump
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pf expression profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of early onset colorectal neoplasias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: amelioration of PaO2/FiO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rating of Urges to Smoke
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of plasma isoprostane and lipoperoxides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Post Operative Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pain levels - visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive function: impulse control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in flower-stringing productivity: weight of flower buds used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Rectal Temperature Above 39.0 Degrees Celsius
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Calculated Glomerular Filtration Rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Healing power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in day and night-time frequency of micturitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in a number of urgency and urge incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Visual analog score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of meals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma glucagon concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Baseline Visual analogue Score (VAS) for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary toxicity symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life due to urinary symptoms
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bowel toxicity symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erectile function adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Symmetry of the mouth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excursion of the mouth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-specific quality-of-life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acceptability of participation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quantifying cannabis consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysthyroid optic neuropathy screening index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in adolescent weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time and efficiency of healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose uptake in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glucose uptake in the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ventricular indexes of preterm infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: brain volumes of preterm infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Child Externalizing Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Complete macroscopic polyp eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Onset meaningful pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Skin Condition Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin Temperature at 30 Min After Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Positive Skin Culture at Axilla
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes from baseline in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes from baseline in clinical labs (blood chemistry, hematology and urinalysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lean Body Mass at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat Mass at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini Mental Status Exam (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Activities of Daily Living (ADCS-ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinician's Global Impression of Change (ADCS-CGIC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 10 meter habitual walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia Symptom Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With QMG Score ≤ 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Stone Passage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biomarkers associated with disease anti-dsDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biomarkers associated with disease complement component 3 (C3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biomarkers associated with disease complement component 4 (C4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number, incidence, and severity of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Survival of the potential liver transplant recipient
Endpoint domain: Mortality/survival
Primary endpoint: tmax - the time of occurrence of Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t - the area under the plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Central Macular Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to clinical readiness for discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Locoregional recurrence free survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of time within glucose target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Major Depressive Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Fugl-Meyer Upper Extremity scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in polysomnography (PSG) data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Epworth Sleepiness Scale questionnaire data
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Difference in Functional Outcomes of Sleep questionnaire data
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Combined clinical efficacy outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score on pain questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Achievement of ≥90% Reduction From Baseline PASI Score (PASI90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: change in airway reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dose Intensity of Vemurafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission at week 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission at week 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission at week 54
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission at week 108
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission at week 162
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of hip displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cmax Maximum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes